An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life

Atsushi Kuga,1 Toshinaga Tsuji,2 Shinji Hayashi,2 Shinji Fujikoshi,3 Hirofumi Tokuoka,1 Aki Yoshikawa,4 Rodrigo Escobar,5 Kazuhide Tanaka,6 Takaharu Azekawa7 1Bio Medicine, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, 2Medical Affairs Department, Shionogi & Co., Ltd., Osaka...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kuga A, Tsuji T, Hayashi S, Fujikoshi S, Tokuoka H, Yoshikawa A, Escobar R, Tanaka K, Azekawa T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	depression duloxetine pain selective serotonin reuptake inhibitors first episode Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c86ec896afe3461f81703781ef0ccbd0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c86ec896afe3461f81703781ef0ccbd0
record_format	dspace
spelling	oai:doaj.org-article:c86ec896afe3461f81703781ef0ccbd02021-12-02T02:28:31ZAn observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life1178-2021https://doaj.org/article/c86ec896afe3461f81703781ef0ccbd02017-08-01T00:00:00Zhttps://www.dovepress.com/an-observational-study-of-duloxetine-versus-ssri-monotherapy-in-japane-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Atsushi Kuga,1 Toshinaga Tsuji,2 Shinji Hayashi,2 Shinji Fujikoshi,3 Hirofumi Tokuoka,1 Aki Yoshikawa,4 Rodrigo Escobar,5 Kazuhide Tanaka,6 Takaharu Azekawa7 1Bio Medicine, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, 2Medical Affairs Department, Shionogi & Co., Ltd., Osaka, 3Statistical Science, 4Scientific Communications, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan; 5Bio-Medicines, Eli Lilly and Company, Indianapolis, IN, USA; 6Hitsuji Clinic, Kusatsu, Japan; 7Shioiri Mental Clinic, Yokosuka, Japan Objective: To examine how clinical and demographic patient baseline characteristics influence effectiveness of duloxetine versus selective serotonin reuptake inhibitor (SSRI) treatment, in real-world Japanese clinical settings of patients with major depressive disorder (MDD) and associated painful physical symptoms (PPS).Methods: This was a multicenter, 12-week, prospective, observational study in patients with MDD (Quick Inventory of Depressive Symptomatology ≥16) and at least moderate PPS (Brief Pain Inventory-Short Form [BPI-SF] average pain ≥3). Patients received duloxetine or SSRIs (escitalopram, sertraline, paroxetine, or fluvoxamine). Assessments were made by using BPI-SF average pain, 17-item Hamilton Rating Scale for Depression (HAM-D17), EuroQol 5-dimension questionnaire, Social Adaptation Self-Evaluation Scale, Global Assessment of Functioning, and ability to work. Predefined subgroups included the number of previous episodes of depression (0 vs ≥1), baseline BPI-SF average pain score (≤6 vs >6), baseline HAM-D17 total score (≤18 vs >18), baseline HAM-D17 retardation (≤7 vs >7) and anxiety somatic subscale scores (≤6 vs >6), and age (<65 vs ≥65 years).Results: Treatment effectiveness was evaluated in 523 patients (duloxetine N=273, SSRIs N=250). Treatment with duloxetine was superior to SSRIs on most outcome measures in patients experiencing their first depressive episode, those with higher baseline PPS levels, and in patients with more severe baseline depression. This was also the case for older patients. In patients with less severe depression, SSRI treatment tended to show more improvements in depression and quality of life measures versus duloxetine treatment. Conclusion: These preplanned subgroup analyses of data from a prospective observational study suggest that, for Japanese MDD patients with PPS, duloxetine is more effective than SSRIs in patients with a first episode of MDD, with more severe depression, or more severe PPS. Keywords: depression, duloxetine, pain, selective serotonin reuptake inhibitors, first episodeKuga ATsuji THayashi SFujikoshi STokuoka HYoshikawa AEscobar RTanaka KAzekawa TDove Medical Pressarticledepressionduloxetinepainselective serotonin reuptake inhibitorsfirst episodeNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 2115-2124 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	depression duloxetine pain selective serotonin reuptake inhibitors first episode Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	depression duloxetine pain selective serotonin reuptake inhibitors first episode Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kuga A Tsuji T Hayashi S Fujikoshi S Tokuoka H Yoshikawa A Escobar R Tanaka K Azekawa T An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
description	Atsushi Kuga,1 Toshinaga Tsuji,2 Shinji Hayashi,2 Shinji Fujikoshi,3 Hirofumi Tokuoka,1 Aki Yoshikawa,4 Rodrigo Escobar,5 Kazuhide Tanaka,6 Takaharu Azekawa7 1Bio Medicine, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, 2Medical Affairs Department, Shionogi & Co., Ltd., Osaka, 3Statistical Science, 4Scientific Communications, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan; 5Bio-Medicines, Eli Lilly and Company, Indianapolis, IN, USA; 6Hitsuji Clinic, Kusatsu, Japan; 7Shioiri Mental Clinic, Yokosuka, Japan Objective: To examine how clinical and demographic patient baseline characteristics influence effectiveness of duloxetine versus selective serotonin reuptake inhibitor (SSRI) treatment, in real-world Japanese clinical settings of patients with major depressive disorder (MDD) and associated painful physical symptoms (PPS).Methods: This was a multicenter, 12-week, prospective, observational study in patients with MDD (Quick Inventory of Depressive Symptomatology ≥16) and at least moderate PPS (Brief Pain Inventory-Short Form [BPI-SF] average pain ≥3). Patients received duloxetine or SSRIs (escitalopram, sertraline, paroxetine, or fluvoxamine). Assessments were made by using BPI-SF average pain, 17-item Hamilton Rating Scale for Depression (HAM-D17), EuroQol 5-dimension questionnaire, Social Adaptation Self-Evaluation Scale, Global Assessment of Functioning, and ability to work. Predefined subgroups included the number of previous episodes of depression (0 vs ≥1), baseline BPI-SF average pain score (≤6 vs >6), baseline HAM-D17 total score (≤18 vs >18), baseline HAM-D17 retardation (≤7 vs >7) and anxiety somatic subscale scores (≤6 vs >6), and age (<65 vs ≥65 years).Results: Treatment effectiveness was evaluated in 523 patients (duloxetine N=273, SSRIs N=250). Treatment with duloxetine was superior to SSRIs on most outcome measures in patients experiencing their first depressive episode, those with higher baseline PPS levels, and in patients with more severe baseline depression. This was also the case for older patients. In patients with less severe depression, SSRI treatment tended to show more improvements in depression and quality of life measures versus duloxetine treatment. Conclusion: These preplanned subgroup analyses of data from a prospective observational study suggest that, for Japanese MDD patients with PPS, duloxetine is more effective than SSRIs in patients with a first episode of MDD, with more severe depression, or more severe PPS. Keywords: depression, duloxetine, pain, selective serotonin reuptake inhibitors, first episode
format	article
author	Kuga A Tsuji T Hayashi S Fujikoshi S Tokuoka H Yoshikawa A Escobar R Tanaka K Azekawa T
author_facet	Kuga A Tsuji T Hayashi S Fujikoshi S Tokuoka H Yoshikawa A Escobar R Tanaka K Azekawa T
author_sort	Kuga A
title	An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
title_short	An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
title_full	An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
title_fullStr	An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
title_full_unstemmed	An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
title_sort	observational study of duloxetine versus ssri monotherapy in japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/c86ec896afe3461f81703781ef0ccbd0
work_keys_str_mv	AT kugaa anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT tsujit anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT hayashis anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT fujikoshis anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT tokuokah anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT yoshikawaa anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT escobarr anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT tanakak anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT azekawat anobservationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT kugaa observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT tsujit observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT hayashis observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT fujikoshis observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT tokuokah observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT yoshikawaa observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT escobarr observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT tanakak observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife AT azekawat observationalstudyofduloxetineversusssrimonotherapyinjapanesepatientswithmajordepressivedisordersubgroupanalysesoftreatmenteffectivenessforpaindepressivesymptomsandqualityoflife
_version_	1718402494097260544

An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life

Ejemplares similares